Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, founded in 2002 and headquartered in Cambridge, Massachusetts, is the world's leading RNA interference (RNAi) therapeutics company. It develops medicines that silence genes causing disease, with activities spanning discovery, development, manufacturing and commercialisation. The company employs more than 1,900 people globally and has advanced RNAi science for over two decades.

Its pipeline includes RNAi-based medicines targeting transthyretin (TTR) amyloidosis, acute hepatic porphyria and primary hyperoxaluria. Technical domains cover RNAi therapeutics, genetic medicine, gene silencing, biopharmaceutical discovery and development, and biologics manufacturing, with commercial operations spanning multiple continents.

Alnylam operates across the biotechnology, biopharmaceuticals, rare diseases, genetic medicine and pharmaceuticals verticals. It describes its culture as award-winning and mission-driven, with a stated commitment to scientific excellence and innovation.